FDA WARNING_LETTER - Rxgoodusa - April 01, 2026

FDA WARNING_LETTER for Rxgoodusa on April 01, 2026. Product: drugs. Access full analysis and detailed observations.

One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.

Record Summary

FDA WARNING_LETTER for Rxgoodusa on April 01, 2026. Product: drugs. Access full analysis and detailed observations.

Violation Codes

21 U.S.C. 321(p)

21 U.S.C. 331(dd)

21 CFR 201

21 U.S.C. 331(a)

21 U.S.C. 331(k)

FD&C Act 201(p)

FD&C Act 503(b)(1)(A)

FD&C Act 201(g)(1)

FD&C Act 301(a)

21 CFR 201.115(a)

Get More Insights

Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.

1.5M+ regulatory data points

Real-time compliance monitoring

Interactive analytics dashboard

Looking for more records? Our platform provides access to thousands of similar regulatory documents with advanced search and filtering capabilities.

Record Information

Company

Rxgoodusa

Inspection Date

April 1, 2026

Product Type

drugs

Office

Office of Drug Security, Integrity, and Response

People

Sangeeta Vaswani Chatterjee (Director)

ID: 85b8960b-4105-4693-a8d3-3a562d0c3b84

View on Dashboard

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox